Related references
Note: Only part of the references are listed.Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab
Emily S. Lebow et al.
JAMA NETWORK OPEN (2023)
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael et al.
CANCER CELL (2022)
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy
Taisuke Araki et al.
THORACIC CANCER (2022)
C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy
Alina Frey et al.
BIOMEDICINES (2022)
Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis
Bao-Wen Tian et al.
IMMUNOTHERAPY (2022)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Cristina Valero et al.
NATURE COMMUNICATIONS (2021)
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
G. Mountzios et al.
ESMO OPEN (2021)
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
KenjiY Morimoto et al.
ONCOIMMUNOLOGY (2021)
Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer
Martine J. Sealy et al.
CLINICAL NUTRITION (2020)
Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care
Geisiane Alves da Silva et al.
CLINICAL NUTRITION (2020)
Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer
Chu Chia-Hsun et al.
THORACIC CANCER (2020)
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Florent Petitprez et al.
FRONTIERS IN IMMUNOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non small cell lung cancer following chemoradiation therapy
Eun-Ah Choe et al.
LUNG CANCER (2019)
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation
Irena Kaplanov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
IL-1 and IL-1 regulatory pathways in cancer progression and therapy
Alberto Mantovani et al.
IMMUNOLOGICAL REVIEWS (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Anamorelin (ONO-7643) for the Treatment of Patients With Non-Small Cell Lung Cancer and Cachexia: Results From a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Japanese Patients (ONO-7643-04)
Nobuyuki Katakami et al.
CANCER (2018)
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
Xun Wang et al.
IMMUNOLOGY LETTERS (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
Ming Jing Shen et al.
ONCOTARGET (2017)
Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy
Hidemitsu Kitamura et al.
CANCER SCIENCE (2017)
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Thomas R. Flint et al.
CELL METABOLISM (2016)
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients
Xiaobin Gu et al.
SCIENTIFIC REPORTS (2016)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma
Akiyoshi Kinoshita et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Bo Hu et al.
CLINICAL CANCER RESEARCH (2014)
Prognostic Value of PLR in Various Cancers: A Meta-Analysis
Xin Zhou et al.
PLOS ONE (2014)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
The Role of IL-1β in the Early Tumor Cell-Induced Angiogenic Response
Yaron Carmi et al.
JOURNAL OF IMMUNOLOGY (2013)
Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients
Yuichiro Hiura et al.
CANCER (2012)
Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system
C. M. Op den Kamp et al.
LUNG CANCER (2012)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
CALPAIN ACTIVITY IS INCREASED IN SKELETAL MUSCLE FROM GASTRIC CANCER PATIENTS WITH NO OR MINIMAL WEIGHT LOSS
Ira J. Smith et al.
MUSCLE & NERVE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer
Donald C. McMillan
PROCEEDINGS OF THE NUTRITION SOCIETY (2008)
Share Paper
